BUZZ-Palisade Bio rises; bowel disease drug set for global conference spotlight
I'm PortAI, I can summarize articles.
Shares of Palisade Biorose 1.7% to $1.78 premarket as the company announced its experimental ulcerative colitis drug, PALI-2108, will be featured at two major medical conferences next year. Early-stage data indicates all patients responded positively with no serious safety issues. Presentations are scheduled for the Crohn’s & Colitis Congress in Las Vegas and the European Crohn’s and Colitis Organisation Congress in Stockholm. The company is also preparing a larger 12-week study and planning research on Crohn’s disease. The stock has increased approximately 42% over the past year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments